Neoepitopes Cancer Vaccine Monotherapy Positive Efficacy Randomized Phase 3 results in Non-Small Cell Lung Cancer with Resistance to Immunotherapy
Time: 12:30 pm
day: Day Two
Details:
- Tedopi is a tumour-specific activating immunotherapy based on highly-selected and optimized tumour neoepitopes
- Positive clinical efficacy of Tedopi versus chemotherapy in a randomized Phase III trial in Non-Small Cell Lung Cancer in patients with secondary resistance after failure of checkpoint inhibitors: Significantly better survival: 44% overall survival at 1-year, versus 27% with chemotherapy; Significantly better safety profile: 3-fold less severe Grade 3-5 adverse events and significantly better quality of life.
